Epirubicin has modest single-agent activity in head and neck cancer but limited activity in metastatic melanoma and colorectal cancer: Phase II studies by the Eastern Cooperative Oncology Group

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 21, Issue 5, 1998, Pages 509-512

  Rosenthal, Mark A ^a,f   Green, Michael ^a   Wiernik, Peter ^b   Borden, Ernest C ^c   Marsh, John C ^d   Haller, Daniel G ^e  

^a NEW YORK UNIVERSITY   (United States)

^b ALBERT EINSTEIN CANCER CENTER   (United States)

^c UNIVERSITY OF MARYLAND   (United States)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Colorectal; Epirubicin; Head and neck; Melanoma

Indexed keywords

DOXORUBICIN;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; BONE MARROW SUPPRESSION; CARDIOTOXICITY; CLINICAL TRIAL; COLORECTAL CANCER; DOSE TIME EFFECT RELATION; DRUG EFFICACY; FEMALE; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MELANOMA; NAUSEA; PHASE 2 CLINICAL TRIAL;

ADULT; AGED; ANTIBIOTICS, ANTINEOPLASTIC; COLORECTAL NEOPLASMS; EPIRUBICIN; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL;

EID: 0031755367     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-199810000-00019     Document Type: Article

References (20)

1. Plosker GL, Faulds D. Epirubicin. a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cancer chemotherapy. Drugs 1993;45:788-856.
2. Rosenthal MA, Kefford R, Raghavan D, Stuart-Harris R. Epirubicin: a phase II study in recurrent small-cell lung cancer. Cancer Chemother Pharmacol 1991;28:220-2.
3. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting the results of cancer treatment. Cancer 1981;47:207-14.
4. Lopez M, Perno CF, Papaldo P, Di Lauro L, Ganzina F, Barduagni A. Phase II study of epirubicin in advanced malignant melanoma. Invest New Drugs 1984;2:315-7.
5. Torti FM, Porzig KJ, Gandara DR, et al. Phase II trial of 4′-epi-doxorubicin in metastatic melanoma. Cancer Treat Rep 1984;68:1509-10.
6. Berman E, Casper E, Howard J, Wittes RE. Phase II trial of 4′-epi-doxorubicin in patients with advanced malignant melanoma. Cancer Treat Rep 1984;68:679-80.
7. Lopez M, Perno CF, Di Lauro L, Papaldo P, Ganzina F, Barduagni A. Controlled study of DTIC versus DTIC plus epirubicin in metastatic malignant melanoma. Invest New Drugs 1984;2:319-22.
8. Ajani JA, Kanojia MD, Bodey GP. Phase II evaluation of 4′-epi-doxorubicin in patients with metastatic colorectal carcinoma. Cancer Treat Rep 1984;68:1507-8.
9. Myers FJ, Lewis B, Mitchell E, et al. Phase II trial of 4′-epi-doxorubicin in advanced colorectal carcinoma: a Northern California Oncology Group study. Cancer Treat Rep 1985;69:143-4.
10. Alberola V, Conde J, Jimeno J, et al. Phase II study with high doses of epirubicin in patients with advanced rectal cancer. Tumori 1989;76:503-4.
11. Molinaro P, Lafleur F, Blum RH. A phase III randomized trial of epirubicin versus 5-fluorouracil in metastatic rectal/sigmoid adenocarcinoma. Am J Clin Oncol 1989;12:332-4.
12. Kouri M, Pyrhonen S, Kuusela P. Elevated CA 19-9 as the most significant prognostic factor in advanced colorectal carcinoma. J Surg Oncol 1992;49:78-85.
13. Penel N, Adenis A, Fournier C, Maes-Dombrowski P, Calier D, Bonneterre J. ECF regimen as salvage treatment in patients with progressive metastatic colorectal carcinoma [Abstract]. Proceedings of the American Society of Clinical Oncology 1996;15:533.
14. Adamo V, Maisano R, Pergolizzi S, et al. Bleomycin, epirubicin, carboplatin (BECA) in the treatment of recurrent and/or squamous cell carcinoma of the head and neck. J Chemother 1997;9:72-6.
15. Paccagnella A, Pappagallo GL, Segati R, et al. Epirubicin, methotrexate and bleomycin in the management of recurrent squamous cell head and neck cancer. A GSTTC randomised phase II study. Eur J Cancer 1993;29A:704-8.
16. Cvitkovic E. Neoadjuvant chemotherapy with epirubicin, cisplatin, bleomycin in undifferentiated nasopharyngeal cancer: preliminary results of an international phase III trial [Abstract]. Proceedings of the American Society of Clinical Oncology 1994;13:915.
17. Greidanus J, Willemse PHB, Sleijfer DT, et al. Phase II study of a 21-day continuous infusion schedule with epirubicin in metastatic colorectal cancer. Eur J Cancer 1988;24:801-2.
18. Verweij J, Herweijer H, Oosterom R, et al. A phase II study of epidoxorubicin in colorectal cancer and the use of cyclosporin-A in anattempt to reverse multi-drug resistance. Br J Cancer 1991;64:361-4.
19. Michael M, Toner GC, Olver IN, Fenessy A, Bishop JF. Phase I dose intensification study of 2-weekly epirubicin with GM-CSF in advanced cancer. Am J Clin Oncol 1997;20:259-62.
20. Pyrhonen SO, Kouri MO. Phase II study of epirubicin sequential methotrexate and 5-fluorouracil for advanced colorectal cancer. Eur J Cancer 1992;28A:1828-32.